New clinical data shows that Eli Lilly’s investigational oncology drug pegilodecakin, in combination with a checkpoint inhibitor, could be a potential new treatment for patients with non-small cell lung cancer and kidney cancer.
Researchers Develop New Class of Lung Cancer Drugs
Chemotherapy, Clinical Trials, Drug-resistant tumors, Francis Crick Institute, G12C KRAS inhibitors, IGF1R Pathway, KRAS gene, KRAS Mutations, Lung adenocarcinoma, Lung Cancer, mTOR Pathway, Mutations, R&D, Researchers, Science Translational Medicine, The Institute of Cancer Research (ICR)Working with a new class of drugs called G12C KRAS inhibitors, the Francis Crick Institute and Institute of Cancer Research developed product combos to stay ahead of drug-resistant tumors.
The cancer treatment Imfinzi was shown to prolong survival in a particularly aggressive type of lung cancer by close to three months in a late-stage clinical trial, as AstraZeneca holds the British drugmaker’s ground in a crowded field against rival immunotherapy drugs.
Lilly’s targeted RET drug shrinks tumors in lung cancer trial
Acquisitions, Advanced lung cancer, Business, Clinical Trials, European Society for Medical Oncology (ESMO), FDA, Gene Abnormalities, Liver Enzymes, Non-Small Cell Lung Cancer, Papillary Thyroid Cancer, R&D, RET Gene, Tumor Shrinkage, Tumors, World Conference on Lung CancerEli Lilly and Co.’s LOXO-292, an experimental cancer drug the company acquired in January 2019 as part of an $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70 percent of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene.
Amgen drug shrinks lung cancer tumors in half of patients: study
Advanced lung cancer, Cancer Cells, Cancer Deaths, Checkpoint Inhibitors, Chemotherapy, Clinical Data, Clinical Trials, Colorectal Cancer, Genetic Mutations, Immune System, KRAS Mutations, Non-Small Cell Lung Cancer, R&D, Tumor Shrinkage, Wall Street, World Conference on Lung CancerAn experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.
Novartis secured U.S. FDA Breakthrough Therapy Designation for the investigational medicine capmatinib, which the company aims to file for approval during 2019 against a mutated form of lung cancer.
OncoCyte Corporation, a developer of novel tests for the early diagnosis and management of lung cancer, announced a definitive agreement to acquire Razor Genomics.
A combination of AstraZeneca’s lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations
AstraZeneca Plc said a late-stage study showed the company’s top-selling drug Tagrisso had significantly helped patients with a type of lung cancer live longer without the disease worsening.
The European Medicine Agency’s Committee for Medicinal Products for Human Use recommended EU approval of Roche’s cancer immunotherapy Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer, the Basel, Switzerland-based company said.
